William Blair Predicts Higher Earnings for Alto Neuroscience

Key Points

• William Blair has raised its FY2025 earnings estimate for Alto Neuroscience to ($2.31) per share, up from a previous estimate of ($2.46), indicating a more optimistic outlook for the company.
• Alto Neuroscience shares are currently rated as a "Moderate Buy" by analysts, with an average target price of $11.00, reflecting a positive sentiment despite recent earnings misses.
• Institutional investors have shown interest in Alto Neuroscience, with several firms acquiring new stakes during the second quarter, indicating growing confidence in the company's potential within the biopharmaceutical sector.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - William Blair lifted their FY2025 earnings estimates for Alto Neuroscience in a research report issued to clients and investors on Monday, October 20th. William Blair analyst M. Minter now expects that the company will earn ($2.31) per share for the year, up from their previous forecast of ($2.46). The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience's Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.99) EPS.

Several other brokerages have also weighed in on ANRO. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Alto Neuroscience in a research report on Monday, August 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Chardan Capital initiated coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They issued a "buy" rating and a $15.00 price target on the stock. Finally, Robert W. Baird raised their price target on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an "outperform" rating in a research note on Monday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $11.00.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $10.22 on Thursday. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $12.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The business's fifty day moving average price is $4.72 and its two-hundred day moving average price is $3.29. The firm has a market capitalization of $276.62 million, a PE ratio of -4.27 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the second quarter worth about $25,000. Ground Swell Capital LLC acquired a new stake in shares of Alto Neuroscience in the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $33,000. AlphaCore Capital LLC boosted its position in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock worth $44,000 after acquiring an additional 10,000 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth about $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.